(Alliance News) - The board of Ulisse Biomed Spa on Thursday evening reviewed and approved the draft financial statements for the year ended Dec. 31, 2023, which closed with a group loss of EUR4.8 million, compared with a loss of EUR6.0 million in the previous year.

The value of production as of December 31, 2023, at the consolidated level amounted to EUR263,153 and was fully attributable to the value of production recorded by UBM. This figure shows a decrease of EUR260,624 compared to fiscal year 2022.

Consolidated EBITDA achieved in 2023 was negative EUR2.1 million and is attributable to the EBITDA achieved by UBM.

The decrease compared to 2022 is attributable to the increase in operating costs detailed above and the sharp decline in the value of production.

The Net Financial Position of the UBM group as of December 31, 2023 was positive by EUR2.3 million.

Ulysses Biomed closed Thursday's session flat at EUR1.23 per share

By Maurizio Carta, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.